SCHEMBL1468665

SCHEMBL1468665

NC1CCCN(c2c(F)cnc3[nH]cc(NC(=O)c4cccnc4)c23)C1

nearest known ligand 0.47

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
PIM2 Q9P1W9 12/20 0.47
PIM3 Q86V86 8/20 0.47
PIM1 P11309 6/20 0.47
MAP4K1 Q92918 1/20 0.46
AAK1 Q2M2I8 2/20 0.45
ROCK2 O75116 3/20 0.44
ROCK1 Q13464 3/20 0.44
CDC42BPB Q9Y5S2 3/20 0.44
CDC42BPA Q5VT25 1/20 0.44
HDAC1 Q13547 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1468662 1.00 PIM2 (0.47) PIM2PIM3PIM1MAP4K1AAK1
Hydrochloric Acid SCHEMBL1467780 0.99 PIM2 (0.46) PIM2PIM3PIM1MAP4K1AAK1
Hydrochloric Acid SCHEMBL1467783 0.99 PIM2 (0.46) PIM2PIM3PIM1MAP4K1AAK1
SCHEMBL1468799 0.90 PIM2 (0.47) PIM2PIM3PIM1AAK1ROCK2
SCHEMBL1468800 0.90 PIM2 (0.47) PIM2PIM3PIM1AAK1ROCK2
SCHEMBL1468400 0.90 PIM2 (0.47) PIM2PIM3PIM1AAK1ROCK2
SCHEMBL1468399 0.90 PIM2 (0.47) PIM2PIM3PIM1AAK1ROCK2
SCHEMBL29599640 0.90 PIM2 (0.47) PIM2PIM3PIM1AAK1ROCK2
SCHEMBL1470547 0.90 PIM2 (0.47) PIM2PIM3PIM1AAK1ROCK2
SCHEMBL1469328 0.89 AAK1 (0.49) PIM2PIM3PIM1MAP4K1AAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9969727-B2 Pyrrolopyridines as kinase inhibitors ARRAY BIOPHARMA INC. (US) 2018-05-15 US disclosed
US-20160368916-A1 PYRROLOPYRIDINES AS KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2016-12-22 US disclosed
US-9365568-B2 Pyrrolopyridines as kinase inhibitors ARRAY BIOPHARMA INC. (US) 2016-06-14 US disclosed
EP-2990407-A1 PYRROLOPYRIDINES AS KINASE INHIBITORS Array Biopharma, Inc. (US) 2016-03-02 EP disclosed
US-20150322061-A1 PYRROLOPYRIDINES AS KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2015-11-12 US disclosed
EP-2307409-B1 PYRROLOPYRIDINES AS KINASE INHIBITORS ARRAY BIOPHARMA INC (US) 2015-08-12 EP disclosed
US-8758830-B2 Pyrrolopyridines as kinase inhibitors ARRAY BIOPHARMA, INC. (US) 2014-06-24 US disclosed
US-20140100369-A1 PYRROLOPYRIDINES AS KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2014-04-10 US disclosed
US-8545897-B2 Pyrrolopyridines as kinase inhibitors ARRAY BIOPHARMA INC. (US) 2013-10-01 US disclosed
US-20130045286-A1 PYRROLOPYRIDINES AS KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2013-02-21 US disclosed
US-8178131-B2 Pyrrolopyridines as kinase inhibitors ARRAY BIOPHARMA INC. (US) 2012-05-15 US disclosed
US-20110070317-A1 PYRROLOPYRIDINES AS KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2011-03-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160368916-A1 PYRROLOPYRIDINES AS KINASE INHIBITORS CHEK2, CHEK1, CDKN1A PIM2 697/4885PIM3 801/4885PIM1 637/4885
US-20140100369-A1 PYRROLOPYRIDINES AS KINASE INHIBITORS CHEK2, CHEK1, CDKN1A PIM2 697/4885PIM3 801/4885PIM1 637/4885
US-20110070317-A1 PYRROLOPYRIDINES AS KINASE INHIBITORS CHEK2, CHEK1, BUB1B PIM2 622/4885PIM3 706/4885PIM1 574/4885
US-20150322061-A1 PYRROLOPYRIDINES AS KINASE INHIBITORS CHEK2, CHEK1, CDKN1A PIM2 697/4885PIM3 801/4885PIM1 637/4885
US-20130045286-A1 PYRROLOPYRIDINES AS KINASE INHIBITORS CHEK2, CHEK1, CDKN1A PIM2 697/4885PIM3 801/4885PIM1 637/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.